Clinical implication of immunohistochemical markers.

Area of Science:

• Pathology and Molecular Diagnostics
• Oncology
• Cancer Biomarkers

Background:

• Accurate cancer diagnosis increasingly relies on complementary techniques.
• Immunohistochemistry aids in identifying diagnostic and prognostic factors.
• These factors can predict patient response to specific therapies.

Purpose of the Study:

• To review the role of specific immunohistochemical markers in cancer diagnosis and therapy prediction.
• To highlight the significance of epidermal growth factor receptor (EGFR) in aggressive tumors and targeted therapy.
• To discuss the diagnostic implications of cytokeratins 7 and 20 in carcinomatous differentiation and hereditary non-polyposis colorectal cancer markers.

Main Methods:

• Review of current literature on immunohistochemical markers.
• Analysis of diagnostic and prognostic implications of selected markers.
• Focus on epidermal growth factor receptor (EGFR), cytokeratins 7 and 20, and microsatellite instability markers.

Main Results:

• Epidermal growth factor receptor (EGFR) overexpression correlates with aggressive tumor behavior and potential for targeted therapy.
• Cytokeratins 7 and 20 expression patterns are crucial for determining carcinomatous differentiation.
• Identification of markers associated with hereditary non-polyposis colorectal cancer (HNPCC) and microsatellite instability.

Conclusions:

• Immunohistochemistry is vital for accurate pathological diagnosis and predicting treatment efficacy.
• Specific markers like EGFR, CK7, CK20, and MSI-related markers offer critical insights for personalized cancer management.
• Pathologists play a key role in integrating these molecular findings for improved patient outcomes.